Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal treatment of H. pylori based on clarithromycin resistance by DPO-PCR
KCT0004945Phase 3Not yet recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clarithromycin in Helicobacter pylori-associated gastritis, Helicobacter pylori-associated peptic ulcer, Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, gastric cancer (GC), sponsored by Ministry of Health & Welfare. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
clarithromycin
03
Conditions
Helicobacter pylori-associated gastritisHelicobacter pylori-associated peptic ulcerGastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissuegastric cancer (GC)
Beyond the preview
Go deeper on KCT0004945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004945.